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Antigens from Mycobacterium tuberculosis (M.tb), have been shown to stimulate human B cell 
responses to unrelated recall antigens in vitro. However, it is not known whether natural M.tb 
infection or whether vaccination with, Mycobacterium bovis BCG, has a similar effect. This study 
investigated the effects of M.tb infection and BCG vaccination on B cell responses to heterologous 
pathogen recall antigens. Antibodies against several bacterial and viral pathogens were quantified 
by ELISA in 68 uninfected controls, 62 individuals with latent TB infection (LTBI) and 107 active 
pulmonary TB (APTB) cases, and 24 recently BCG‑vaccinated adolescents and naive controls. Antibody 
avidity was investigated using surface plasmon resonance and B cell ELISPOTs were used to measure 
plasmablast and memory B cell responses (MBC) in APTB cases and healthy donor controls. APTB was 
associated with higher levels of antibodies to respiratory syncytial virus and measles virus, compared 
to uninfected controls. BCG vaccination did not alter levels of antibodies against heterologous 
pathogens. Tetanus toxoid (TT)‑specific antibody avidity was increased in APTB cases in comparison 
to uninfected individuals and the ratio of TT‑specific plasmablasts to MBCs in the APTB cases was 7:1. 
M.tb infection is associated with increased antibody responses to heterologous pathogens in human 
subjects.
The Mycobacterium tuberculosis complex (MTBC) is made up of several mycobacterial species that cause tuber-
culosis (TB), a disease that affects millions of people worldwide. There were 10 million cases of TB disease 
in 2018, 1.45 million deaths, and a quarter of the world’s population is estimated to be  infected1. Despite the 
seriousness of the disease caused by MTBC, some of these pathogens have use as immunotherapies due to their 
potent immunostimulatory properties. The most important member of the MTBC, Mycobacterium tuberculosis 
(M.tb), is well known for its adjuvant properties. It is a constituent of Freund’s complete adjuvant and is thought 
to improve vaccine responses through its stimulatory effect on antigen presenting cells such as dendritic cells 
and  macrophages2. Mycobacterium bovis Bacille Calmette Guerin (BCG) has been used to treat bladder cancer 
for over 30 years3. The exact mechanism of action has not been fully elucidated, but the common hypothesis is 
that BCG draws innate immune cells into the bladder and primes them to attack cancer  cells4.
Increasing evidence has been put forward supporting a potential role for BCG in the protection of infants 
from diseases caused by heterologous pathogens. Early studies in Guinea Bissau showed a decrease in deaths 
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from infectious diseases among low birth weight infants who were given BCG vaccine at  birth5,6. These effects 
are thought to be as a result of improved function of innate immune cells brought about by cellular epigenetic 
modifications induced by  BCG7. There may also be non-specific effects on the adaptive immune system. Ota 
et al.8 described higher hepatitis B virus-specific antibody responses in infants who were given BCG in addition 
to hepatitis B vaccination at birth, compared to those who were only vaccinated with hepatitis B. A more recent 
study by Ritz et al.9 reported that the level of antibodies elicited by pneumococcal vaccination of infants at 2, 
4 and 6 months of age were higher in those infants who were given BCG at birth compared to those who were 
not. BCG may therefore improve immune responses to vaccines given at the same time as BCG or those given 
following BCG vaccination, in a non-specific manner.
The studies highlighted above describe the effect of mycobacteria on responses to concurrently administered 
vaccine antigens or those given after vaccination with mycobacterial preparations. However, studies in the past 
have shown that purified protein derivative (PPD) from M.tb can stimulate secretion of antibodies against mea-
sles, rubella and herpes simplex viruses from human peripheral blood mononuclear cells (PBMCs) in vitro10. 
This finding suggests that M.tb may be able to enhance antibody/B-cell memory responses generated from 
previous exposure to unrelated pathogen-derived antigens. The exact immunological mechanism underlying 
this observation is not yet known; however, it is possible that Mycobacterium antigens could non-specifically 
activate pathogen-specific memory B cells (MBCs), resulting in the expansion of antibody-secreting cells and a 
subsequent rise in antibody levels. Human MBCs are prone to activation by polyclonal stimulation; studies by 
Bernasconi et al.11 have shown that stimulation of these cells by bacterial CpG (cytosine-phosphate-guanine) 
DNA or by T cell cytokines can lead to their proliferation and expansion into antibody-secreting cells. However, 
this hypothesis has not been investigated in regard to Mycobacterium tuberculosis exposure. Furthermore, it is 
not known whether natural M.tb infection has the same non-specific stimulatory effect on antibody responses to 
recall antigens from heterologous pathogens. We also do not know whether recent vaccination with the related 
species, M. bovis BCG has a similar effect on serological recall responses to unrelated antigens.
This study characterised antibody responses to heterologous pathogen recall antigens in uninfected controls, 
individuals with a latent TB infection (LTBI) or active pulmonary TB cases (APTB) cases participating in a TB 
household contact study in Uganda, as well as adolescent recipients of the BCG vaccine and their age-matched 
naïve controls from the United Kingdom (UK). Additionally, polyclonal activation of MBCs was explored as 
a possible mechanism by studying frequencies of tetanus toxoid (TT)-specific plasmablasts and MBCs in the 
APTB cases and healthy donors.
Results
Demographics. The characteristics of the Ugandan TB household contact study participants have been 
reported  previously12 and are shown in Table 1 below. In summary, APTB cases and individuals with LTBI were 
older than the uninfected individuals and there was a larger proportion of males in the APTB group in compari-
son to the other two groups. There were also more HIV positive individuals and a larger proportion of people of 
low socioeconomic class among the APTB group.
The adolescents studied in the UK were all aged between 12 and 13 years, had no previous BCG scar and 
were tuberculin skin test  negative13.
M.tb infection state is associated with increased antibody responses to unrelated patho‑
gens. Antibody responses were compared across groups of uninfected individuals, individuals with LTBI and 
APTB cases from Uganda to determine the impact of M.tb infection state on antibody responses to heterologous 
pathogens. Since we were interested in recall responses, we studied antibodies against antigens contained in 
childhood vaccines, such as TT, diphtheria toxoid (DT) and measles virus (MV). We also measured antibodies 
specific for infections that our participants may have had a high chance of encountering in childhood in this set-
ting. These included respiratory syncytial virus (RSV)14,  adenovirus15, Kaposi’s sarcoma herpes virus (KSHV)16, 
cytomegalovirus (CMV)17 and Epstein–Barr virus (EBV)18. M.tb PPD was included as a positive control indica-
tive of mycobacterial exposure. Initial crude analyses revealed evidence of differences in the levels of antibodies 
specific to PPD, DT, RSV, MV, KSHV ORF73, KSHV 8.1 and CMV antigens across the groups (Fig. 1). There 
were also differences in total IgG antibody concentrations (Supplementary Fig. S1). There was no evidence of 
differences in EBV and adenovirus-specific antibodies across the groups (Supplementary Fig. S1).
In the final analyses, associations between M.tb infection status and antibody responses were determined 
by means of linear regression analysis using the uninfected controls as the baseline comparison group while 
Table 1.  Study participant characteristics. P values are from chi-square tests of associations. LTBI latent 
tuberculosis infection, SES socioeconomic status, APTB active pulmonary tuberculosis. a Individuals were 
either of low or medium SES.
Characteristic Uninfected (n = 68) LTBI (n = 62) APTB (n = 102) P value
Mean age and range (years) 14 (1, 66) 23 (1, 66) 29 (18, 53)  < 0.0001
Females 43 (63.24%) 41 (65.1%) 44 (43.1%) 0.006
HIV positive 4 (5.9%) 5 (7.9%) 40 (39.2%)  < 0.0001
Low  SESa 31 (46.3%) 31 (50.8%) 58 (63.7%) 0.070
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adjusting for the effects of age, gender, HIV infection status and socioeconomic status. APTB was associated with 
higher levels of anti-PPD, anti-RSV and anti-MV antibodies compared to the uninfected individuals (Table 2). 
We observed evidence of increased antibodies against TT, DT and KSHV K8.1 antigens (Table 2) and total 
IgG levels in APTB (Supplementary Table S1), however this was not statistically significant after correcting for 
multiple testing. There were no associations between M.tb infection status and anti-EBV or anti-adenovirus 
antibodies, in agreement with findings from the crude analyses (Supplementary Table S1). We also observed 
positive associations between LTBI and anti-DT, anti-TT and anti-PPD antibodies but these did not reach the 
threshold of statistical significance.
BCG vaccination is not associated with increased antibody responses to unrelated patho‑
gens. Next, we determined whether recent vaccination with the related species, Mycobacterium bovis BCG, 
was also associated with elevated antibody responses to unrelated recall pathogen antigens. Antibody responses 
were evaluated in a UK cohort of adolescents comprising a test group of 12 individuals who received BCG, and 
13 age-matched BCG naïve controls, and the two compared at timepoints before and 3 weeks after vaccination 
of the test group. This cohort allowed us to compare BCG vaccinated individuals to a BCG naïve group, which 
we could not do in the Ugandan participants because BCG is routinely given to infants as part of the Uganda 
National Expanded Programme on  Immunisation19.
We observed no differences in antibody responses to any antigen, including PPD, between the BCG vaccinated 
individuals and naïve controls at the 3 week time point (Fig. 2b). These results mirrored non-significant differ-
ences observed between the two groups before BCG vaccination (Fig. 2a). The fold change in antibody over the 
three week period was also compared between BCG vaccinated individuals and naïve controls and no statistically 
significant differences were observed (Supplementary Fig. S2). These findings indicate that BCG vaccination may 
not be able to boost antibody responses to heterologous pathogens, or at least not within the 3 week time frame.
Avidity of tetanus toxoid‑specific antibodies is increased in APTB. We determined whether the 
observed increases in antibody responses to unrelated recall antigens in M.tb infected individuals was accompa-
nied by changes in their avidity or overall binding strength. An increase in avidity could point to MBCs being the 
source of heterologous pathogen antigen-specific antibodies because these cells would have already undergone 
affinity maturation. To this end, the avidity of antibodies against TT and measles virus haemagglutinin (MVHA) 
antigens were investigated using surface plasmon resonance (SPR). Due to limitations in sample volumes, only 
88 of the 237 KTB study participants’ samples were tested.
Initial crude comparisons showed marginal evidence of a difference in dissociation rate (the measure of 
avidity) in TT-specific antibodies across the three groups (Supplementary Fig. S3). For the final analysis, lin-
ear regression was used to evaluate associations between M.tb infection state and antibody avidity using the 
Figure 1.  Variations in antibody responses to heterologous pathogens across M.tb infection state. The 
horizontal bars shown are median IgG antibody optical densities in each group. Antibody responses were 
compared across uninfected controls (n = 68), individuals with LTBI (n = 62) and APTB cases (n = 107). The 
p values shown correspond to results from Kruskal–Wallis test (*p < 0.05; **p < 0.01). PPD purified protein 
derivative, TT tetanus toxoid, DT diphtheria toxoid, RSV respiratory syncytial virus, MV measles virus, KSHV 
Kaposi’s sarcoma herpesvirus, CMV cytomegalovirus.
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uninfected controls as the baseline comparison group while adjusting for the effects of age, gender, HIV infection 
status and socioeconomic status (Table 3). APTB was associated with the presence of TT-specific antibodies of a 
slower dissociation rate, a sign of higher avidity. A similar positive association was observed with LTBI but this 
was not statistically significant after correcting for multiple testing. We also observed similarly weak evidence to 
suggest that APTB was associated with MVHA specific antibodies of a slower dissociation rate (Table 3). These 
results lend credence to the hypothesis that the increased antibody responses against heterologous pathogen 
recall antigens observed in M.tb infection arise from antigen-specific MBCs.
Tetanus toxoid‑specific plasmablasts are higher than tetanus toxoid‑specific memory B cells 
in APTB. In order to explore the possibility that M.tb infection may be driving differentiation of MBCs spe-
cific to unrelated recall antigens into plasmablasts in our study participants, we examined the frequency of TT-
specific MBCs and plasmablasts in 48 APTB cases and 115 healthy donors using B cell ELISPOT assays.
We had limited PBMC numbers from the APTB cases and so MBC frequencies were ascertained in 18 of 
the APTB cases while plasmablast frequencies were evaluated in the rest (n = 30). The ratio of the median fre-
quencies of TT-specific plasmablasts to MBC in the APTB cases was 7:1 (8.75:1.25; Fig. 3). The high abundance 
of TT-specific plasmablasts relative to MBCs in the APTB cases provides evidence of polyclonal activation of 
Table 2.  Associations between Mycobacterium tuberculosis infection status and concentrations of IgG 
antibodies to heterologous pathogen antigens. Linear regression analysis of antibody data from 67 uninfected 
controls, 62 individuals with LTBI and 89 APTB cases. Statistically significant associations following 
adjusting for multiple testing are shown in a bold font. GMR geometric mean ratio, LTBI latent tuberculosis 
infection, APTB active pulmonary tuberculosis, PPD purified protein derivative, TT tetanus toxoid, DT 
diphtheria toxoid, RSV respiratory syncytial virus, MV measles virus, KSHV Kaposi’s sarcoma herpesvirus, 
CMV cytomegalovirus. § Adjusted for age, gender, socioeconomic status and HIV infection status. ƒ q values 
were calculated using the Bonferroni method for comparisons between M.tb infection states and uninfected 
individuals.
Antibody optical density Adjusted GMR (95%CI) § p value Q value ƒ
Anti-PPD
Uninfected 1
LTBI 1.286 (0.995–1.663) 0.055 1.000
APTB 3.326 (2.446–4.524)  < 0.001 0.002
Anti-TT
Uninfected 1
LTBI 1.448 (0.969–2.164) 0.071 1.000
APTB 1.608 (1.082–2.390) 0.019 0.418
Anti-DT
Uninfected 1
LTBI 1.443 (1.002–2.079) 0.049 1.000
APTB 1.516 (1.123–2.047) 0.007 0.154
Anti-RSV
Uninfected 1
LTBI 0.922 (0.806–1.053) 0.230 1.000
APTB 1.178 (1.066–1.301) 0.001 0.022
Anti-MV
Uninfected 1
LTBI 1.074 (0.798–1.445) 0.639 1.000
APTB 1.599 (1.286–1.988)  < 0.001 0.002
Anti-KSHV ORF73
Uninfected 1
LTBI 1.051 (0.926–1.192) 0.441 1.000
APTB 1.142 (0.994–1.312) 0.062 1.000
Anti-KSHV K8.1
Uninfected 1
LTBI 1.112 (0.695–1.778) 0.658 1.000
APTB 1.969 (1.201–3.227) 0.007 0.154
Anti-CMV
Uninfected 1
LTBI 0.893 (0.615–1.298) 0.553 1.000
APTB 1.029 (0.782–1.354) 0.837 1.000
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antigen-specific MBCs in APTB. This process may be driving their differentiation into plasmablasts and could 
explain the increased levels of antibodies against heterologous pathogen recall antigens observed in active TB 
disease.
Efforts to determine TT-specific plasmablast to MBC ratio in the healthy donors for comparison were not 
possible because TT-specific plasmablasts were not readily detected during preliminary analyses. However, 
high frequencies of TT-specific MBC were detected in these individuals at levels above those seen in the APTB 
Figure 2.  Antibody responses to heterologous pathogens in BCG vaccinated individuals and their age-matched 
BCG naïve controls. (a) antibody responses before BCG vaccination. (b) antibody responses 3 weeks after BCG 
vaccination. The horizontal bars shown are median IgG antibody optical density in each group. The p values 
shown correspond to results from Wilcoxon rank sum test (*p < 0.05; **p < 0.01) from comparing antibody 
responses in BCG vaccinated (n = 12) and BCG naïve controls (n = 13). PPD purified protein derivative, TT 
tetanus toxoid, DT diphtheria toxoid, RSV respiratory syncytial virus, MV measles virus, CMV cytomegalovirus, 
EBV Epstein–Barr virus.
Table 3.  Association between M.tb infection state and SPR derived TT and MVHA specific antibody 
dissociation rates. 23 uninfected controls, 25 individuals with LTBI and 34 APTB cases. Statistically significant 
associations following adjusting for multiple testing are shown in a bold font. GMR geometric mean ratio, LTBI 
latent tuberculosis infection, APTB active pulmonary tuberculosis. ¥ Adjusted for age, gender, socioeconomic 
status and HIV infection status. ∫ q values were calculated using the Bonferroni method for comparisons 
between M.tb infection states and uninfected individuals.
Dissociation rate E-06 [kd(s−1)] Adjusted GMR (95%CI)¥ p value q  value∫
Anti-TT antibodies
Uninfected 1
LTBI 0.728 (0.548–0.967) 0.029 0.116
APTB 0.725 (0.582–0.902) 0.004 0.016
Anti-MVHA antibodies
Uninfected 1
LTBI 0.971 (0.915–1.030) 0.331 1.000
APTB 0.927 (0.861–0.998) 0.044 0.176
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cases (Fig. 4). Although TT-specific MBCs have been shown to remain in circulation years after vaccination, 
TT-specific plasmablasts are short-lived, disappearing within 2 weeks after antigen  exposure20. This may explain 
the lack of detectable TT-specific plasmablasts in healthy donors.
Discussion
This study highlights for the first time a possible role for natural M.tb infection in the boosting of antibody 
immunity to heterologous pathogens that individuals may have been previously exposed to, through infection or 
immunisation, and shows that vaccination with the related bacterium, Mycobacterium bovis BCG does not have 
a similar effect. The increase in the levels and avidity of these antibodies in M.tb infected individuals may mean 
that MBCs are their likely source. Additionally, the abundance of TT-specific plasmablasts relative to TT-specific 
MBCs in active TB disease provides evidence to support the hypothesis that M.tb infection drives polyclonal 
activation of MBCs generated against unrelated recall antigens. If this property can be exploited, it could lead to 
the production of immunological therapies than can be used to boost serological memory to a wide variety of 
infections, particularly in people with waning immunity such as the elderly.
The fact that the increase in antibody responses to heterologous pathogens was most evident in APTB disease 
may mean that this non-specific effect is most pronounced in an environment of actively replicating tubercle 
bacilli. Indeed, previous research has shown that active TB disease is associated with increases in CMV-specific 
Figure 3.  TT-specific plasmablasts are higher than TT-specific MBCs in APTB. MBC responses were evaluated 
in 18 APTB cases while PB responses were evaluated in 30 APTB cases. The p values are from Wilcoxon-rank 
sum tests. MBC memory B cells, PB plasmablasts, TT tetanus toxoid.
Figure 4.  Lower TT-specific MBC frequencies in APTB cases compared to healthy donor controls. MBC 
responses were evaluated in 115 healthy donors and 18 APTB cases. The p values are from Wilcoxon-rank sum 
tests. MBC memory B cells, TT tetanus toxoid.
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:14324  | https://doi.org/10.1038/s41598-020-71044-4
www.nature.com/scientificreports/
 antibodies21,22, however, these studies attributed the rise in antibodies to concurrent infection with CMV rather 
than as a marker of serological memory. A study by de Paus et al.23 observed higher levels of influenza-specific 
antibodies in individuals with TB and recognized that in addition to concurrent infection there was a possibility 
that these may have arisen as a result of mycobacterial driven non-specific increases in antibodies.
The observation that BCG vaccination did not have a similar effect may mean that proteins unique to M.tb 
may mediate the increase in antibody responses to these heterologous pathogens observed in APTB. Alterna-
tively, this may point to the effect of BCG mycobacterial load at the site of inoculation, which may fall short of 
the M.tb bacillary load observed in the lungs during active TB disease. The lack of significant stimulation of 
anti-mycobacterial antibodies in the BCG vaccinated recipients, in contrast to the more than threefold rise in 
the same in the APTB cases (Table 1) supports this reasoning. The lack of antibody response may also simply be 
due to the timing after vaccination. A later time point may have allowed the accrual of BCG-specific antibodies; 
we were not able to assess this in our study.
Antibody responses to recall antigens from heterologous pathogens were increased in both level and avidity 
in M.tb infection. This gave further evidence that the source of these antibodies are MBCs because these cells 
would have already undergone affinity maturation, and as a consequence produce antibodies of high avidity. A 
study by Zimmerman et al.24 argues that the primary source of anti-mycobacterial antibodies in TB disease are 
MBCs, as demonstrated by the high level of somatic hypermutations in antibody-secreting cells isolated in this 
disease state. Tubercle bacilli may drive the activation of MBCs specific to a wide variety of pathogen antigens 
including those specific for M.tb. A similar phenomenon has been demonstrated for other infections such as 
 malaria25, hepatitis  C26 and hantavirus pulmonary  disease27. Bernasconi et al. (2006) have previously shown 
that MBCs are easily activated by polyclonal stimuli such as bacterial DNA and T cell cytokines produced fol-
lowing vaccination. Additionally, innate immune cytokines such as IFN-α and IL-6 promote the activation of 
B cells, their differentiating into plasmablasts and their secretion of  antibodies29. It is, therefore, possible that 
mycobacterial products and the cytokine milieu present during human M.tb infection may activate MBCs lead-
ing to their differentiation to antibody-secreting cells. Our B cell ELISPOT data illustrated an abundance of 
TT-specific plasmablasts relative to TT-specific MBCs in APTB. Frequencies of TT-specific MBCs were lower 
in APTB cases in comparison to healthy donors while TT-specific plasmablasts were not readily detected in the 
latter. These observations further support the hypothesis that M.tb drives MBC polyclonal activation. It may be 
important to assess the impact of anti-mycobacterial drug treatment in APTB cases on antibody responses to 
heterologous pathogens in future studies. A reduction in antibody responses following treatment may further 
support our hypothesis. It is not clear how M.tb may benefit from increasing recall antibody responses to other 
pathogens. However, we speculate that this process may aid in the survival of M.tb within the host by limiting 
host death as a result of infection by unrelated pathogens.
It is unclear as to why APTB was only significantly associated with antibody responses to some pathogen 
recall antigens and not others. This may relate to varied rates of exposure to the different infections over time. 
Multiple recent exposures to some of the pathogens investigated could generate new antibody responses which 
may mask any “benefit” gleaned from mycobacterial driven MBC activation. Certain pathogens such as EBV 
has been shown to establish latency in  MBCs30. This virus has also been shown to increase proliferation and 
activation of B cells and add to the effect of known TLR agonists such as  CpG31. This would support the idea of 
increased EBV antibody responses in M.tb infected individuals, however, this was not observed in our study.
This study has a few limitations. We assumed that the antibody responses detected against the chosen heter-
ologous pathogen antigens in our study participants arose as a result of past exposure via infection or vaccination. 
However, recent or current exposure to these multiple pathogens, although unlikely, was possible. The individuals 
included in the study were of varied, age, gender, socioeconomic and HIV infection status reflecting common 
demographic characteristics in Ugandan populations. HIV infection is known to significantly alter the immune 
responses and was strongly associated with M.tb infection status (Table 1). We were able to adjust for the effects 
of HIV, as well as the other measured potential confounders in the regression analyses to reduce their impact on 
the associations. Further analyses performed in only HIV negative individuals revealed similar associations as 
those observed in the total study population (Supplementary Table S2 and S3). Our findings are mostly based 
on IgG responses in our study population, however, it may be important in the future to look at other relevant 
antibody isotypes such as IgM. Individuals able to resist M.tb infection despite exposure to TB have been shown 
to have IgM in addition to IgG anti-mycobacterial  antibodies32. The presence of IgM antibodies in sera has also 
been associated with increased inhibition of infection of epithelial by M.tb33.
On the whole, these data point to a hitherto unknown role for M.tb in the maintenance of serological memory 
generated against past infections and vaccinations. It has been hypothesised that exposure to infections in later 
life could help maintain antibody responses to a broad set of pathogens in the absence of their specific antigens. 
This process is proposed to be due to polyclonal stimulation of antigen  MBCs11,28 and the data presented here 
supports this. However, further experimentation is required to confirm the mechanism involved and identify the 
specific M.tb antigens mediating this process. This may involve in vitro cell culture assays using various mycobac-
terial stimulants and B cell ELISPOTs to measure antibody secreting cells. This research may aid in the develop-
ment of therapeutics to boost antibody immunity to heterologous pathogens. It is envisaged that this treatment 
could be useful in ageing populations in whom antibody responses to specific infections are known to wane.
Materials and methods
Study populations and design. A cross-sectional study design was used to determine whether there were 
associations between M.tb infection status and antibody responses to heterologous pathogen recall antigens in 
study participants from a TB household contact study based in Uganda investigating the effect of coinfections 
in humans on their susceptibility to infection with M.tb34. Individuals with APTB and their household contacts 
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(HHCs) were recruited from the suburbs of Kampala. The APTB cases were all adults over 18 years of age and 
had either only recently began anti-TB treatment or received treatment for less than 4 weeks. APTB was ascer-
tained using acid fast bacilli sputum microscopy. Individuals with LTBI were identified from among healthy 
HHCs using the tuberculin skin test and QuantiFERON-TB Gold in-tube (QFT-GIT) test. The HHCs that tested 
positive on both these tests were classified as having LTBI whereas those that tested negative on both tests were 
classified as uninfected controls. A total of 68 uninfected controls, 62 individuals with LTBI and 107 APTB 
cases were included in our study. QFT-GIT nil supernatant samples from these individuals were used for the 
antibody analyses. The choice of QFT-GIT supernatants was because serum samples were not available for all the 
individuals studied. We have previously shown that there are no differences between antibody concentrations 
obtained from assaying serum and those from assaying QFT-GIT  supernatants35.
Stored plasma samples from adolescents participating in a UK based prospective study on BCG responses 
were used to determine whether BCG vaccination was associated with non-specific increases in antibody 
responses to heterologous pathogen recall antigens. These individuals were part of a UK government programme 
on BCG vaccination in schools in the year 2005 and were invited to take part in a research study that sought to 
identify immune responses involved in BCG mediated protection against TB. The adolescents studied included 
12 subjects who were given BCG and then followed up after three weeks as well as 13 age-matched controls who 
did not receive BCG and were followed up for the same period of time. All the subjects had no previous BCG scar 
(a sign of earlier BCG vaccination) and had a negative TST prior to  immunisation13. Samples obtained from these 
individuals before BCG vaccination and at the 3 week timepoint were analysed. This cohort was chosen because it 
gave us the unique opportunity to compare BCG vaccinated and unvaccinated controls, something which could 
not be easily done in Ugandan cohorts considering BCG is part of the immunisation schedule in the  country19.
In order to investigate MBC polyclonal activation as a possible cause of the elevated antibody responses to 
heterologous pathogens in people with TB, cryopreserved PBMCs from 48 APTB cases from the TB household 
contact study and fresh PBMCs from 115 healthy donor controls were analysed to determine the effect of an 
active TB infection on the frequencies of TT-specific plasmablasts and MBCs. The healthy donors were recruited 
from a voluntary HIV counselling and testing clinic at the Uganda Virus Research Institute. They were all HIV 
negative, aged 18–55 years and found to be healthy by a clinician.
These studies were all exploratory and the sample size was determined by the availability of sufficient samples 
and reagents for laboratory analyses.
Laboratory assays. In‑house antigen‑specific IgG ELISA. Immulon 4 HBX microtiter plates (Thermo Sci-
entific, USA) were coated with 50 µl/well of 5 µg/ml DT, 5 µg/ml TT (both from National Institute for Biological 
Standards and Control), 5 µg/ml M.tb PPD (Serum Statens Institute, Denmark), 5 µg/ml RSV antigen, 5 µg/ml 
measles grade 2 antigen, 5 µg/ml adenovirus grade 2 antigen, 1.25 µg/ml Epstein–Barr viral capsid (all from 
Microbix, Biosystems, Canada) or 0.1% (w/v) skimmed milk (control for nonspecific binding) in carbonate-
bicarbonate buffer (pH 9.6) at 4  °C overnight. Following overnight incubation, the plates were washed four 
times with 1 × PBS (pH 7.4) containing 0.05% Tween 20 (PBS-T). The plates were then blocked with 150 µl/well 
1% (w/v) skimmed milk in PBS-T for 2 h at room temperature. A dilution of 1 in 100 of each sample in 0.1% 
skimmed milk PBS-T (assay buffer) was made and 50 µl was then added to the antigen-coated and control wells. 
After an incubation of 2 h at room temperature, the wells were washed as before and incubated with 50 µl/well 
polyclonal rabbit anti-human IgG conjugated with horseradish peroxidase (Dako, Denmark) at 0.5 µg/ml for an-
other hour at room temperature. Plates were then washed four times and enzyme activity detected by incubation 
with 100 µl/well o-phenylenediamine (Sigma) containing hydrogen peroxide for 15 min at room temperature in 
the dark. The reaction was stopped by addition of 25 µl/well 2 M sulphuric acid and thereafter the optical density 
(OD) measured at a test wavelength of 490 nm and a reference wavelength of 630 nm in an ELISA plate reader 
(Biotek). The ODs from the control wells were subtracted from the test antigen wells to eliminate background 
antibody levels.
KSHV antibody ELISA. Immulon 4 HBX microtiter plates pre-coated with K8.1 or ORF73 were kindly pro-
vided by the Viral Oncology Section, AIDS and Cancer Virus Program, SAIC-Frederick, Inc., NCI-Frederick, 
Frederick, MD 21,702. In the coating procedure, 100 µl/well of 2 µg/ml K8.1 or ORF73 diluted in 0.05 M carbon-
ate/bicarbonate buffer, pH 10 or 1 × PBS respectively was incubated in plate wells overnight at 4 °C. The plates 
were washed three times with PBS-T and then blocked with 280 µl/well of assay buffer [2.5% (w/v) BSA (Sigma), 
2.5% (v/v) normal donor goat serum (Equitech-Bio), 0.005% (v/v) Tween 20, 0.005% (v/v) Triton X-100 in 
1 × PBS] for 3 h at 37 °C and thereafter stored at 80 °C until use.
The plates were thawed at 37 °C in preparation for the assay and washed three times with PBST. A 1 in 100 
dilution of the sample or controls was prepared and then 100 µl was added per well in duplicate. Each plate had 3 
positive and 2 negative control samples for quality control. After an incubation of 90 min at 37 °C, the wells were 
washed five times and incubated with 100 µl/well goat anti-human IgG conjugated with alkaline phosphatase 
(Roche Diagnostics) diluted 1 in 5,000 for 30 min at 37 °C. The plates were washed five times and enzyme activity 
detected by incubation with 100 µl/well 1-step p-nitrophenyl phosphate substrate solution (Thermo Scientific 
Pierce, USA) for 30 min at room temperature in the dark. This reaction was stopped by the addition of 50 µl/
well of 3 N NaOH and then the plates were read at a wavelength of 405 nm.
CMV antibody ELISA. Platelia CMV IgG ELISA was used to measure CMV-specific antibodies as per the 
manufacturer’s  instructions36. Briefly, diluted samples, standards of known anti-CMV antibody concentration 
and controls were added to microtitre plates pre-coated with CMV antigens. The plates were incubated with the 
samples at 37 °C for 45 min and thereafter washed with buffer. A conjugate composed of horseradish peroxi-
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dase enzyme bound onto anti-human IgG monoclonal antibody was then added to each well and incubated for 
45 min at 37 °C. The plates were washed and an enzyme substrate was added to each well followed by a 15-min 
incubation at room temperature. After this, a stop solution was added and the OD read at 450 nm wavelength.
Total IgG antibody ELISA. Human IgG total Ready-SET-Go (Affymetrix ebioscience) was used to measure 
total IgG following the manufacturer’s  instructions37. In the procedure, Immulon 4 HBX microtiter plates were 
coated with 100 µl/well purified anti-human IgG monoclonal antibody overnight at 4 °C. The plates were then 
washed twice with wash buffer and incubated with 250 µl/well blocking buffer for 2 h at room temperature. 
The plates were washed twice and eight, recombinant human IgG controls were prepared and the samples were 
diluted 1 in 100,000. A volume of 100 µl/well of the prepared standards and samples was added to the plates and 
then incubated for 2 h at room temperature. In the next step, the plates were washed four times and incubated 
with 100 µl/well HRP-conjugated anti-human IgG monoclonal detection antibody for 1 h at room temperature. 
The plates were washed four times and incubated with 100 µl/well tetramethylbenzidine (TMB) substrate solu-
tion for 15 min at room temperature in the dark. After this duration, the reaction was stopped by addition of 
100 µl/well stop solution and the plates read at 450 nm wavelength.
Surface plasmon resonance. The avidity of antibodies directed against TT and MVHA antigens was evaluated. 
These antigens were immobilised onto CM5 sensor chips (Biacore, GE Healthcare, Amersham) by amine cou-
pling to a level of 2000 RU.
Samples were diluted 1 in 3 in HBSPE (10 mM HEPES pH 7.4 containing 0.15 M NaCl, 3 mM EDTA and 
0.005% (w/v) Surfactant P20; GE Healthcare) and run through Bio-Gel P-30 (Bio-Rad, UK) polyacrylamide 
gel spin columns to minimise non-specific binding. They were further diluted 1 in 8 in HBSPE running buffer 
containing 1% (w/v) carboxymethyl-dextran sodium salt (Sigma) and analysed in the Biacore 3000 instrument 
at a temperature of 25 °C. A 90 µl volume of sample was injected over the chip surface at a rate of 15 µl/min 
followed by a dissociation time of 8 min. Prior to analysis of the next sample, the chips were regenerated with 
50 mM HEPES containing 3 M MgCl2 and 25% (v/v) ethylene glycol, followed by 20 mM glycine pH 1.5 and 
re-equilibration in HBSPE.
BIA evaluation software version 4.1.1 was used for data analysis and control flow-cell traces with immobilised 
alpha-1 antitrypsin background were subtracted from test flow cell data. A Langmuir 1:1 dissociation model was 
used to determine the dissociation rate between 10 and 300 s post sample injection.
B cell ELISPOT. We used in-house in vitro and ex vivo B cell ELISPOTS to determine the frequency of TT-
specific plasmablasts and MBCs respectively in APTB cases and healthy donors following methods described 
by Sebina et al.38,39. Cryopreserved PBMCs were thawed, resuspended in RPMI (Gibco by Life Technologies) 
containing 10% (v/v) fetal bovine serum, 2 mM l-glutamine (both from Sigma-Aldrich, UK) and 1 × penicil-
lin–streptomycin (Invitrogen). The cells were then rested for 4–6 h at 37 °C and 5%  CO2.
In the in vitro ELISPOT, PBMCs at a cell density of 1 × 106 cells/ml were stimulated with a mixture of 25 ng/
ml human IL-10 (R&D Systems, UK), 0.5 µg/ml of pokeweed mitogen (PWM), 6 µg/ml of CpG oligodeoxynu-
cleotide, 1.2 mg/ml Staphylococcus aureus Cowan, 50 µM ß-mercaptoethanol at 37 °C and 5%  CO2 for six days. 
Approximately 4 × 105 of the cultured cells were then transferred to each well of 96-well filter (Merck Milipore) 
pre-coated with 2 µg/ml TT in 1 × PBS or only 1 × PBS. The plates were sealed and incubated for 6 h at 37 °C and 
5%  CO2 after which biotin-SP conjugated affinipure fragment donkey antihuman IgG (Jackson ImmunoResearch) 
was added to the plate wells to aid in the detection of anti-TT specific antibody secreting cells. After overnight 
incubation at 4 °C, streptavidin-AKP (BD biosciences) was added and the plates incubated for an hour at room 
temperature followed by AP-conjugate substrate (Bio-Rad, USA) to develop the spots. After 10 min the plate wells 
were rinsed with water and left to dry before they were read using an AID ELISPOT reader (AID Diagnostika, 
Germany). The number of MBCs was then expressed as the total number of spots per million cells.
The ex vivo ELISPOT involved the direct transfer of the rested PBMCs to the 96-well filter plates at a cell 
density of 4 × 105 cells/well. All the subsequent steps were similar to those described for the in vitro ELISPOT.
Data analysis. Study data were analysed using Stata Release statistical package and GraphPad Prism soft-
ware. The initial analyses were made using the Kruskal–Wallis test to compare antibody responses across the 
groups of uninfected controls, individuals with LTBI and APTB cases. Linear regression analysis with bootstrap 
confidence intervals was then be used to determine associations between M.tb infection status and log trans-
formed antibody  responses12,17. Adjusting was done for the effects of potential confounders such as HIV infec-
tion, age, socioeconomic status and gender. In order to account for multiple testing Q values were computed for 
every comparison between the M.tb infected groups and uninfected individuals, using the Bonferroni method. 
The Wilcoxon rank sum test was used to compare antibody responses between BCG vaccinated individuals and 
BCG naïve controls as well as frequencies of MBCs and PBs in APTB cases.
ethics statement. This study was conducted following recommendations provided by the Makerere Uni-
versity School of Biomedical Sciences Higher Degrees and Research Ethics Committee. The research protocol 
was approved by Research & Ethics Committees at the Makerere University School of Biomedical Sciences and 
School of Medicine, the Uganda Virus Research Institute, the London School of Hygiene & Tropical Medicine 
and Uganda National Council for Science and Technology. Informed written consent was obtained from all the 
adult study participants in accordance with the declaration of Helsinki. The parents of the adolescent partici-
pants provided written informed consent and verbal consent was obtained from the participants themselves.
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